ZURICH-Novartis AG Monday said a late-stage study showed little difference between its top-selling Gilenya drug and a placebo for treating a difficult form of multiple sclerosis.. Basel-based Novartis said the Phase III trial of the treatment, which is already approved for treating relapsing multiple sclerosis, failed to show significant difference...
  